Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20478656 | 0.91 | DRD4 (0.50) | PIN1HTR1AMTNR1AMTNR1B | |
| SCHEMBL20478601 | 0.84 | CA12 (0.46) | HTR1AMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL20478923 | 0.81 | CYP1A2 (0.51) | PIN1MTNR1AMTNR1BCYP1A2MAPT | |
| SCHEMBL9457823 | 0.81 | HTR1A (0.51) | PIN1HTR1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL9457826 | 0.81 | HTR1A (0.51) | PIN1HTR1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL9457829 | 0.81 | HTR1A (0.51) | PIN1HTR1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL7216300 | 0.79 | ACHE (0.40) | PIN1ACHECYP1A2CYP2C9 | |
| SCHEMBL20478665 | 0.78 | PIN1 (0.52) | PIN1HTR1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL1847083 | 0.78 | PIN1 (0.52) | PIN1HTR1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL7935873 | 0.77 | MTNR1A (0.43) | PIN1HTR1AMTNR1AMTNR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4215520-A1 | TMEM16A MODULATORS | TMEM16A LIMITED (GB) | 2023-07-26 | — | — | EP | disclosed |
| EP-3743406-B9 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2023-03-08 | — | — | EP | disclosed |
| EP-3743406-B1 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20220395512-A1 | COMPOUNDS | TMEM16A LTD (GB) | 2022-12-15 | — | — | US | disclosed |
| US-11364246-B2 | Compounds | TMEM16A LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| WO-2019145726-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
| WO-1994002463-A1 | ANTIHYPERTENSIVE 1,4-DIHYDROPYRIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | PIN1 4764/4885HTR1A 619/4885MTNR1A 1545/4885 |
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | PIN1 944/4885HTR1A 5/4885MTNR1A 42/4885 |
| US-11364246-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | PIN1 4834/4885HTR1A 731/4885MTNR1A 1181/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | PIN1 944/4885HTR1A 5/4885MTNR1A 42/4885 |
| US-20220395512-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1A | PIN1 4835/4885HTR1A 832/4885MTNR1A 1473/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | PIN1 4835/4885HTR1A 832/4885MTNR1A 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.